These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 25947160)

  • 1. How to handle an industry in disruption: Intervene or laissez-faire?
    Munos B
    Sci Transl Med; 2015 May; 7(286):286ps12. PubMed ID: 25947160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transformational, transactional among physician and laissez-faire leadership among physician executives.
    Xirasagar S
    J Health Organ Manag; 2008; 22(6):599-613. PubMed ID: 19579573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical innovation in the United States. Factors affecting future performance.
    Pollard MR
    Int J Technol Assess Health Care; 1993; 9(2):167-73. PubMed ID: 8458697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The destructiveness of laissez-faire leadership behavior.
    Skogstad A; Einarsen S; Torsheim T; Aasland MS; Hetland H
    J Occup Health Psychol; 2007 Jan; 12(1):80-92. PubMed ID: 17257068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creating alternative incentives for pharmaceutical innovation.
    Lyles A
    Clin Ther; 2006 Jan; 28(1):126-8. PubMed ID: 16490586
    [No Abstract]   [Full Text] [Related]  

  • 6. [Major changes in the global pharmaceutical industry].
    Hedner T; Thornblad T; Edgar B; Cowlrick I; Olausson M; Lind L; Klofsten M
    Lakartidningen; 2012 Feb 15-21; 109(7):324-5. PubMed ID: 22574425
    [No Abstract]   [Full Text] [Related]  

  • 7. Laissez-Faire Leadership and Affective Commitment: the Roles of Leader-Member Exchange and Subordinate Relational Self-concept.
    Robert V; Vandenberghe C
    J Bus Psychol; 2021; 36(4):533-551. PubMed ID: 34720397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
    Lanthier M; Miller KL; Nardinelli C; Woodcock J
    Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From what we know to what we do: lessons learned from the translational CLAHRC initiative in England.
    Currie G; Lockett A; El Enany N
    J Health Serv Res Policy; 2013 Oct; 18(3 Suppl):27-39. PubMed ID: 24127358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical innovation at the crossroads.
    Laubach GD; Gelijns AC
    Issues Sci Technol; 1995; 11(3):33-40. PubMed ID: 10141894
    [No Abstract]   [Full Text] [Related]  

  • 11. Into the valley of death: research to innovation.
    Hudson J; Khazragui HF
    Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biopharmaceutical industry's commitment to innovation and to the future of health care].
    Marini G
    Recenti Prog Med; 2006 Nov; 97(11):626-33. PubMed ID: 17252719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Home bids $8.5 billion to buy New Jersey drug company.
    Scott L
    Mod Healthc; 1994 Aug; 24(32):12. PubMed ID: 10135368
    [No Abstract]   [Full Text] [Related]  

  • 14. An examination of "nonleadership": from laissez-faire leadership to leader reward omission and punishment omission.
    Hinkin TR; Schriesheim CA
    J Appl Psychol; 2008 Nov; 93(6):1234-48. PubMed ID: 19025245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macro trends in pharmaceutical innovation.
    Cohen FJ
    Nat Rev Drug Discov; 2005 Jan; 4(1):78-84. PubMed ID: 15688075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BIG INNOVATION IN SMALL PLACES.
    Alsever J
    Fortune; 2016 Jun; 173(7):29-30. PubMed ID: 27491136
    [No Abstract]   [Full Text] [Related]  

  • 17. The applicability of Bass's model of transformational, transactional, and laissez-faire leadership in the hospital administrative environment.
    Spinelli RJ
    Hosp Top; 2006; 84(2):11-8. PubMed ID: 16708688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovation drives success in Switzerland's biotech scene.
    Whyte B
    Drug Discov Today; 2005 Oct; 10(20):1342-5. PubMed ID: 16253869
    [No Abstract]   [Full Text] [Related]  

  • 19. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 20. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.